Seeking Alpha

Amarin -5% after FDA delays ANCHOR SPA appeal, MKM downgrades

  • Amarin (AMRN -5%) is downgraded to Neutral from Buy at MKM Partners after it announced the FDA had delayed making a determination on the company's request to reinstate the ANCHOR clinical trial Special Protocol Assessment agreement.
  • MKM continues to expect AMRN to have a difficult time significantly growing Vascepa prescriptions in the face of a smaller sales force and new ACC/AHA lipid guidelines that essentially only recommend statins for lipid management, and the firm does not expect AMRN to secure a near-term partnership for the drug.
Comments (2)
  • johnsonstarfish
    , contributor
    Comments (23) | Send Message
    Guess who wants cheap shares?
    16 Jan, 06:37 PM Reply Like
  • Teddie
    , contributor
    Comments (51) | Send Message
    Not I -- wouldn't touch this thing.
    17 Jan, 04:31 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: